...
机译:评价ER,PgR,HER-2,Ki-67,cyclin D1和nm23-H1作为局部晚期乳腺癌新辅助化疗病理完全反应的预测指标
Division of Breast Surgery, Department of General Surgery, General Hospital of Chinese People’s Liberation Army, No. 28, Fuxing Rd, Beijing, 100853, People’s Republic of China;
Department of Pathology, General Hospital of Chinese People’s Liberation Army, Beijing, People’s Republic of China;
Division of Breast Surgery, Department of General Surgery, General Hospital of Chinese People’s Liberation Army, No. 28, Fuxing Rd, Beijing, 100853, People’s Republic of China;
Division of Breast Surgery, Department of General Surgery, General Hospital of Chinese People’s Liberation Army, No. 28, Fuxing Rd, Beijing, 100853, People’s Republic of China;
Division of Breast Surgery, Department of General Surgery, General Hospital of Chinese People’s Liberation Army, No. 28, Fuxing Rd, Beijing, 100853, People’s Republic of China;
Division of Breast Surgery, Department of General Surgery, General Hospital o;
Locally advanced breast cancer; Neoadjuvant chemotherapy; Docetaxel; Epirubicin; Cyclin D1; nm23-H1;
机译:ER,PgR,HER-2,Ki-67,cyclin D1和nm23-H1的评估可作为局部晚期乳腺癌对新辅助化疗的病理完全反应的预测指标。
机译:ER,PgR,HER-2,Ki-67,拓扑异构酶IIα和nm23-H1蛋白表达可预测局部晚期乳腺癌对新辅助化疗的病理完全反应
机译:ER,PgR,HER-2,Ki-67,拓扑异构酶IIalpha和nm23-H1蛋白表达可预测局部晚期乳腺癌对新辅助化疗的病理完全反应。
机译:利用综合成像,分子和人口统计数据预测对乳腺癌新辅助化疗的病理完全反应
机译:在乳腺癌新辅助化疗后使用术前Mri引导的活检来预测病理完全缓解
机译:评价ERPgRHER-2和Ki-67作为可手术乳腺癌对新辅助蒽环类药物化疗反应的预测指标
机译:评价ER,PgR,HER-2和Ki-67作为可手术乳腺癌对新辅助蒽环类药物化疗反应的预测指标